TR201907729T4 - Bir anti-çekirdekleştirici ajan içeren farmasötik bileşim. - Google Patents

Bir anti-çekirdekleştirici ajan içeren farmasötik bileşim. Download PDF

Info

Publication number
TR201907729T4
TR201907729T4 TR2019/07729T TR201907729T TR201907729T4 TR 201907729 T4 TR201907729 T4 TR 201907729T4 TR 2019/07729 T TR2019/07729 T TR 2019/07729T TR 201907729 T TR201907729 T TR 201907729T TR 201907729 T4 TR201907729 T4 TR 201907729T4
Authority
TR
Turkey
Prior art keywords
nucleating agent
pharmaceutical composition
composition containing
salt
drug
Prior art date
Application number
TR2019/07729T
Other languages
English (en)
Inventor
M Artino Laura
T Cruanes Maria
Xu Wei
Zhu Honggang
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36565788&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR201907729(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of TR201907729T4 publication Critical patent/TR201907729T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Katı dozaj formlarında oral uygulamaya yönelik olarak uygun farmasötik bileşimler açıklanır. Bileşimler, bir tuz formunda bir etkili miktarda bir ilaç bileşiği içerir, burada ilaç tuzu belirli pH koşulları altında ilaç bileşiğinin bir daha az çözünebilir formuna dönüştürülmesi ve bir anti-çekirdekleştirici ajan ile karakterize edilir.
TR2019/07729T 2004-12-03 2005-12-02 Bir anti-çekirdekleştirici ajan içeren farmasötik bileşim. TR201907729T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63285904P 2004-12-03 2004-12-03

Publications (1)

Publication Number Publication Date
TR201907729T4 true TR201907729T4 (tr) 2019-06-21

Family

ID=36565788

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/07729T TR201907729T4 (tr) 2004-12-03 2005-12-02 Bir anti-çekirdekleştirici ajan içeren farmasötik bileşim.

Country Status (9)

Country Link
US (1) US8771733B2 (tr)
EP (2) EP1819323B2 (tr)
JP (3) JP2008521929A (tr)
CN (1) CN101068533B (tr)
AU (1) AU2005311714B2 (tr)
CA (1) CA2588465C (tr)
ES (1) ES2727577T5 (tr)
TR (1) TR201907729T4 (tr)
WO (1) WO2006060681A2 (tr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA87884C2 (uk) 2004-12-03 2009-08-25 Мерк Энд Ко., Инк. Безводна кристалічна калієва сіль інгібітора віл-інтегрази
EP1819323B2 (en) 2004-12-03 2023-03-22 Merck Sharp & Dohme Corp. Pharmaceutical composition containing an anti-nucleating agent
EP1904067B2 (en) 2004-12-03 2017-10-11 Merck Sharp & Dohme Corp. Pharmaceutical formulation of carboxamide hiv integrase inhibitors containing a release rate controlling composition
BRPI0518741A2 (pt) * 2004-12-03 2008-12-02 Merck & Co Inc uso de uma combinaÇço de uma droga diretamente metabolizada por ugt1a1 ou um seu sal farmaceuticamente aceitÁvel e atazanavir ou um seu sal farmaceuticamente aceitÁvel, e, combinaÇço farmacÊutica para administraÇço oral a um mamÍfero
CN101595133B (zh) * 2006-10-27 2012-11-14 比利时胶囊公司 羟丙基甲基纤维素硬胶囊及制备方法
CN101197832B (zh) * 2007-12-13 2012-01-25 华为技术有限公司 一种实现iptv业务的方法、系统、装置
EP2438062B1 (en) * 2009-06-02 2015-07-29 Hetero Research Foundation Process for the preparation of amorphous raltegravir potassium
US9649311B2 (en) * 2009-10-26 2017-05-16 Merck Sharp & Dohme Corp. Solid pharmaceutical compositions containing an integrase inhibitor
EP2545048B1 (en) * 2010-04-01 2014-10-08 Teva Pharmaceutical Industries Ltd. Raltegravir salts and crystalline forms thereof
US9968607B2 (en) 2011-04-25 2018-05-15 Hetero Research Foundation Pharmaceutical compositions of raltegravir, methods of preparation and methods of use therof
US12472475B2 (en) 2018-02-02 2025-11-18 The General Hospital Corporation Methods of supercooling aqueous samples
EP4093380A1 (en) 2020-01-23 2022-11-30 Lupin Limited Pharmaceutical compositions of raltegravir
US20230277587A1 (en) * 2022-03-03 2023-09-07 Dermacisen, S.A. Food supplement for oral administration

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4540566A (en) * 1984-04-02 1985-09-10 Forest Laboratories, Inc. Prolonged release drug dosage forms based on modified low viscosity grade hydroxypropylmethylcellulose
JPH0347124A (ja) * 1989-04-20 1991-02-28 Fujisawa Pharmaceut Co Ltd 経口吸収用製剤
CA2019324C (en) * 1989-07-10 1996-08-20 Robert L. Jerzewski Fosinopril tablet formulations
JP2707023B2 (ja) * 1992-07-01 1998-01-28 株式会社大塚製薬工場 経口吸収用製剤
AU6329599A (en) † 1998-09-28 2000-04-17 Glaxo Group Limited Antiviral combinations comprising (s)-2-ethyl -7-fluoro -3-oxo-3, 4-dihydro -2h-quinoxaline -1-carboxylic acid isopropyl ester
PL348596A1 (en) * 1998-12-25 2002-06-03 Shionogi & Co Aromatic heterocycle compounds having hiv integrase inhibiting activities
GB9922963D0 (en) * 1999-09-28 1999-12-01 Pfizer Ltd Polymorphic salt
AU783981C (en) * 2000-05-08 2007-05-03 Janssen Pharmaceutica N.V. HIV replication inhibitors
US7115565B2 (en) † 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
ATE355064T1 (de) * 2001-10-26 2006-03-15 Angeletti P Ist Richerche Bio Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase
IL161337A0 (en) * 2001-10-26 2004-09-27 Angeletti P Ist Richerche Bio N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase
AU2003220186A1 (en) † 2002-04-10 2003-10-27 Merck And Co., Inc. Pharmaceutical compositions containing an hiv integrase inhibitor and a nonionic surfactant
NZ540729A (en) * 2002-12-27 2008-03-28 Angeletti P Ist Richerche Bio Tetrahydro-4H-pyrido[1,2-a]pyrimidines and related compounds useful as HIV integrase inhibitors
DK1583542T3 (da) † 2003-01-14 2008-09-22 Gilead Sciences Inc Sammensætninger og fremgangsmåder til antiviral kombinationsterapi
UA87884C2 (uk) * 2004-12-03 2009-08-25 Мерк Энд Ко., Инк. Безводна кристалічна калієва сіль інгібітора віл-інтегрази
EP1904067B2 (en) 2004-12-03 2017-10-11 Merck Sharp & Dohme Corp. Pharmaceutical formulation of carboxamide hiv integrase inhibitors containing a release rate controlling composition
BRPI0518741A2 (pt) 2004-12-03 2008-12-02 Merck & Co Inc uso de uma combinaÇço de uma droga diretamente metabolizada por ugt1a1 ou um seu sal farmaceuticamente aceitÁvel e atazanavir ou um seu sal farmaceuticamente aceitÁvel, e, combinaÇço farmacÊutica para administraÇço oral a um mamÍfero
EP1819323B2 (en) 2004-12-03 2023-03-22 Merck Sharp & Dohme Corp. Pharmaceutical composition containing an anti-nucleating agent
US9968607B2 (en) 2011-04-25 2018-05-15 Hetero Research Foundation Pharmaceutical compositions of raltegravir, methods of preparation and methods of use therof

Also Published As

Publication number Publication date
WO2006060681A3 (en) 2006-10-12
EP1819323A4 (en) 2012-07-18
AU2005311714B2 (en) 2010-09-30
AU2005311714A1 (en) 2006-06-08
EP1819323B2 (en) 2023-03-22
US20080118559A1 (en) 2008-05-22
JP2013063999A (ja) 2013-04-11
US8771733B2 (en) 2014-07-08
ES2727577T5 (en) 2025-04-02
CN101068533B (zh) 2011-04-27
EP3165220B2 (en) 2024-11-13
EP3165220B1 (en) 2019-04-03
WO2006060681A2 (en) 2006-06-08
EP1819323B1 (en) 2016-11-16
CA2588465A1 (en) 2006-06-08
ES2727577T3 (es) 2019-10-17
JP2012184250A (ja) 2012-09-27
EP3165220A1 (en) 2017-05-10
CA2588465C (en) 2013-10-01
JP2008521929A (ja) 2008-06-26
CN101068533A (zh) 2007-11-07
EP1819323A2 (en) 2007-08-22

Similar Documents

Publication Publication Date Title
EA201171429A1 (ru) Противораковое соединение и содержащая его фармацевтическая композиция
TR201907729T4 (tr) Bir anti-çekirdekleştirici ajan içeren farmasötik bileşim.
CO6300932A2 (es) Composicion solida termoestable que comprende sustancias mejoradas de permeabilidad para ingredientes farmaceuticos activos de permeabilidad deficiente
NZ597237A (en) Sublingual apomorphine
MX2011012627A (es) Derivados aminobutiricos sustituidos como inhibidores de nepralisina.
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
DK2041133T3 (da) Derivater af imadazol [1,2-A] pyridine-2-carboxamider, fremstilling deraf og anvendelse deraf i terapeutik
ATE493973T1 (de) Irbesartan enthaltende pharmazeutische zusammensetzung
UA116334C2 (uk) Тверді форми дозування бендамустину
UA122762C2 (uk) Пероральна композиція 9-[(2,2-диметилпропіламіно)-метил]-міноцикліну або його солі, тверда пресована дозована форма, композиція для ін'єкцій, застосування та спосіб приготування фармацевтичної композиції
MY140630A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
TNSN07337A1 (en) Pharmaceutical composition comprising an indolylmaleimide derivative
MY143568A (en) 11b-hsd1 inhibitors for the treatment of diabetes
SE0301701D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
ATE388695T1 (de) Pharmazeutische zusammensetzung enthaltend ein benzimidazol-derivat gemischt mit mikrokristalliner cellulose
MX2007006635A (es) Formulacion farmaceutica de inhibidores dela carboxamida vih integrasa que contienen una composicion que controla la velocidad de liberacion.
TW200626581A (en) Compounds, compositions containing them, preparation thereof and uses thereof
EA200600377A1 (ru) Новая композиция
MY142792A (en) Azolopyridin-2-one derivatives as inhibitors of lipases and phospholipases
TR200803177A2 (tr) Antihiperglisemik etkili metformîn - pioglitazon formülasyonu.
WO2007145563A8 (en) Benzimidazole derivatives which are to be used as antagonist for the cb1-receptor
ZA200804499B (en) Compounds for the inhibition of apoptosis
EA201290983A1 (ru) Пероральные фармацевтические дисперсные композиции
PL1906931T3 (pl) Ulepszona kompozycja farmaceutyczna zawierająca inhibitor ACE i sposób jej wytwarzania
RU2009119869A (ru) 5-[(2r)-[2-[2-[2-(2,2,2-трифторэтокси)фенокси]этил]амино]пропил]-2-метоксибензолсульфонамид